The stock of Synairgen plc (LON:SNG) hit a new 52-week low and has GBX 14.23 target or 12.00% below today’s GBX 16.17 share price. The 7 months bearish chart indicates high risk for the GBX 15.42 million company. The 1-year low was reported on Nov, 4 by Barchart.com. If the GBX 14.23 price target is reached, the company will be worth GBX 1.85 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. The stock decreased 1.97% or GBX 0.33 on November 4, hitting GBX 16.17. About 23,262 shares traded hands. Synairgen plc (LON:SNG) has declined 36.54% since April 6, 2016 and is downtrending. It has underperformed by 37.63% the S&P500.
Synairgen plc (LON:SNG) Ratings Coverage
Out of 2 analysts covering Synairgen PLC (LON:SNG), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Synairgen PLC has been the topic of 12 analyst reports since July 22, 2015 according to StockzIntelligence Inc. The firm has “Corporate” rating by FinnCap given on Wednesday, October 12. The rating was maintained by FinnCap with “Corporate” on Tuesday, November 17. N+1 Singer maintained it with “Buy” rating and GBX 47 target price in Thursday, January 28 report. The firm has “Corporate” rating given on Tuesday, March 22 by FinnCap. The firm has “Buy” rating by N+1 Singer given on Thursday, September 22. N+1 Singer maintained the shares of SNG in a report on Wednesday, August 5 with “Buy” rating. The stock has “Buy” rating given by N+1 Singer on Wednesday, July 22. N+1 Singer maintained Synairgen plc (LON:SNG) on Wednesday, September 16 with “Buy” rating. The stock of Synairgen plc (LON:SNG) has “Corporate” rating given on Wednesday, August 5 by FinnCap. The stock of Synairgen plc (LON:SNG) has “Corporate” rating given on Tuesday, August 30 by FinnCap.
More recent Synairgen plc (LON:SNG) news were published by: Reuters.com which released: “Synairgen slumps by a third as AstraZeneca ditches asthma drug study” on October 12, 2016. Also Fool.Co.Uk published the news titled: “Are Synairgen plc or Immupharma plc better investments than AstraZeneca plc?” on June 07, 2016. Marketwatch.com‘s news article titled: “Synairgen PLC” with publication date: June 10, 2011 was also an interesting one.
Synairgen plc is a holding company. The Firm is engaged in the drug discovery and development of therapies for respiratory diseases, particularly in the areas, including severe asthma, chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis (IPF). The company has a market cap of 15.42 million GBP. The Firm uses its human biology BioBank platform to discover and develop therapies for respiratory disease. It currently has negative earnings. Using the BioBank platform, it has developed a number of tissue models, which include In vitro and Ex vivo models.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.